Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: Efficacy, safety and non-compartmental pharmacokinetics

Andreas H. Groll, Corina E. Gonzalez, Neelam Giri, Krystina Kligys, William Love, Joanne Peter, Erwin Feuerstein, John Bacher, Stephen C. Piscitelli, Thomas J. Walsh

Research output: Contribution to journalArticle

Abstract

The activity of liposomal nystatin against invasive pulmonary aspergillosis was investigated in persistently neutropenic rabbits. Treatment groups included liposomal nystatin at dosages of 1,2 and 4 mg/kg/day intravenously, or amphotericin B deoxycholate 1 mg/kg/day administered intravenously after normal saline loading. As compared with untreated controls, liposomal nystatin administered at 2 and 4 mg/kg/day prolonged survival and reduced fungus-mediated tissue injury and excess lung weight at post-mortem in a similar manner to amphotericin B. Although amphotericin B was superior in clearing infected lung tissue, treatment with all regimens of liposomal nystatin led to a significant reduction in pulmonary fungal tissue burden. During treatment, ultrafast CT-scan demonstrated ongoing resolution of pulmonary lesions at 2 and 4 mg/kg/day, but not at 1 mg/kg/day. With the exception of mild increases in blood urea nitrogen (BUN) and serum creatinine values during treatment at 2 and 4 mg/kg/day, which were similar to those found in amphotericin B-treated rabbits, liposomal nystatin was well tolerated. Preliminary pharmacokinetic studies in non-infected animals established linear drug disposition of liposomal nystatin in plasma over the investigated dosage range and peak plasma levels above the MIC for the test strain after multiple daily dosing for 7 days. Liposomal nystatin increased survival and provided reduced tissue injury, effective microbiological clearance and tolerable side effects in experimental pulmonary aspergillosis in persistently neutropenic rabbits, thus providing a rational basis for further investigations in clinical trials.

Original languageEnglish (US)
Pages (from-to)95-103
Number of pages9
JournalThe Journal of antimicrobial chemotherapy
Volume43
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Pulmonary Aspergillosis
Nystatin
Pharmacokinetics
Rabbits
Safety
Amphotericin B
Lung
Invasive Pulmonary Aspergillosis
Blood Urea Nitrogen
Lung Injury
Creatinine
Fungi
Clinical Trials
Weights and Measures
Wounds and Injuries
Serum

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits : Efficacy, safety and non-compartmental pharmacokinetics. / Groll, Andreas H.; Gonzalez, Corina E.; Giri, Neelam; Kligys, Krystina; Love, William; Peter, Joanne; Feuerstein, Erwin; Bacher, John; Piscitelli, Stephen C.; Walsh, Thomas J.

In: The Journal of antimicrobial chemotherapy, Vol. 43, No. 1, 1999, p. 95-103.

Research output: Contribution to journalArticle

Groll, AH, Gonzalez, CE, Giri, N, Kligys, K, Love, W, Peter, J, Feuerstein, E, Bacher, J, Piscitelli, SC & Walsh, TJ 1999, 'Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: Efficacy, safety and non-compartmental pharmacokinetics', The Journal of antimicrobial chemotherapy, vol. 43, no. 1, pp. 95-103. https://doi.org/10.1093/jac/43.1.95
Groll, Andreas H. ; Gonzalez, Corina E. ; Giri, Neelam ; Kligys, Krystina ; Love, William ; Peter, Joanne ; Feuerstein, Erwin ; Bacher, John ; Piscitelli, Stephen C. ; Walsh, Thomas J. / Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits : Efficacy, safety and non-compartmental pharmacokinetics. In: The Journal of antimicrobial chemotherapy. 1999 ; Vol. 43, No. 1. pp. 95-103.
@article{e817e9a3e478425abc4afdc53bb4395c,
title = "Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: Efficacy, safety and non-compartmental pharmacokinetics",
abstract = "The activity of liposomal nystatin against invasive pulmonary aspergillosis was investigated in persistently neutropenic rabbits. Treatment groups included liposomal nystatin at dosages of 1,2 and 4 mg/kg/day intravenously, or amphotericin B deoxycholate 1 mg/kg/day administered intravenously after normal saline loading. As compared with untreated controls, liposomal nystatin administered at 2 and 4 mg/kg/day prolonged survival and reduced fungus-mediated tissue injury and excess lung weight at post-mortem in a similar manner to amphotericin B. Although amphotericin B was superior in clearing infected lung tissue, treatment with all regimens of liposomal nystatin led to a significant reduction in pulmonary fungal tissue burden. During treatment, ultrafast CT-scan demonstrated ongoing resolution of pulmonary lesions at 2 and 4 mg/kg/day, but not at 1 mg/kg/day. With the exception of mild increases in blood urea nitrogen (BUN) and serum creatinine values during treatment at 2 and 4 mg/kg/day, which were similar to those found in amphotericin B-treated rabbits, liposomal nystatin was well tolerated. Preliminary pharmacokinetic studies in non-infected animals established linear drug disposition of liposomal nystatin in plasma over the investigated dosage range and peak plasma levels above the MIC for the test strain after multiple daily dosing for 7 days. Liposomal nystatin increased survival and provided reduced tissue injury, effective microbiological clearance and tolerable side effects in experimental pulmonary aspergillosis in persistently neutropenic rabbits, thus providing a rational basis for further investigations in clinical trials.",
author = "Groll, {Andreas H.} and Gonzalez, {Corina E.} and Neelam Giri and Krystina Kligys and William Love and Joanne Peter and Erwin Feuerstein and John Bacher and Piscitelli, {Stephen C.} and Walsh, {Thomas J.}",
year = "1999",
doi = "10.1093/jac/43.1.95",
language = "English (US)",
volume = "43",
pages = "95--103",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits

T2 - Efficacy, safety and non-compartmental pharmacokinetics

AU - Groll, Andreas H.

AU - Gonzalez, Corina E.

AU - Giri, Neelam

AU - Kligys, Krystina

AU - Love, William

AU - Peter, Joanne

AU - Feuerstein, Erwin

AU - Bacher, John

AU - Piscitelli, Stephen C.

AU - Walsh, Thomas J.

PY - 1999

Y1 - 1999

N2 - The activity of liposomal nystatin against invasive pulmonary aspergillosis was investigated in persistently neutropenic rabbits. Treatment groups included liposomal nystatin at dosages of 1,2 and 4 mg/kg/day intravenously, or amphotericin B deoxycholate 1 mg/kg/day administered intravenously after normal saline loading. As compared with untreated controls, liposomal nystatin administered at 2 and 4 mg/kg/day prolonged survival and reduced fungus-mediated tissue injury and excess lung weight at post-mortem in a similar manner to amphotericin B. Although amphotericin B was superior in clearing infected lung tissue, treatment with all regimens of liposomal nystatin led to a significant reduction in pulmonary fungal tissue burden. During treatment, ultrafast CT-scan demonstrated ongoing resolution of pulmonary lesions at 2 and 4 mg/kg/day, but not at 1 mg/kg/day. With the exception of mild increases in blood urea nitrogen (BUN) and serum creatinine values during treatment at 2 and 4 mg/kg/day, which were similar to those found in amphotericin B-treated rabbits, liposomal nystatin was well tolerated. Preliminary pharmacokinetic studies in non-infected animals established linear drug disposition of liposomal nystatin in plasma over the investigated dosage range and peak plasma levels above the MIC for the test strain after multiple daily dosing for 7 days. Liposomal nystatin increased survival and provided reduced tissue injury, effective microbiological clearance and tolerable side effects in experimental pulmonary aspergillosis in persistently neutropenic rabbits, thus providing a rational basis for further investigations in clinical trials.

AB - The activity of liposomal nystatin against invasive pulmonary aspergillosis was investigated in persistently neutropenic rabbits. Treatment groups included liposomal nystatin at dosages of 1,2 and 4 mg/kg/day intravenously, or amphotericin B deoxycholate 1 mg/kg/day administered intravenously after normal saline loading. As compared with untreated controls, liposomal nystatin administered at 2 and 4 mg/kg/day prolonged survival and reduced fungus-mediated tissue injury and excess lung weight at post-mortem in a similar manner to amphotericin B. Although amphotericin B was superior in clearing infected lung tissue, treatment with all regimens of liposomal nystatin led to a significant reduction in pulmonary fungal tissue burden. During treatment, ultrafast CT-scan demonstrated ongoing resolution of pulmonary lesions at 2 and 4 mg/kg/day, but not at 1 mg/kg/day. With the exception of mild increases in blood urea nitrogen (BUN) and serum creatinine values during treatment at 2 and 4 mg/kg/day, which were similar to those found in amphotericin B-treated rabbits, liposomal nystatin was well tolerated. Preliminary pharmacokinetic studies in non-infected animals established linear drug disposition of liposomal nystatin in plasma over the investigated dosage range and peak plasma levels above the MIC for the test strain after multiple daily dosing for 7 days. Liposomal nystatin increased survival and provided reduced tissue injury, effective microbiological clearance and tolerable side effects in experimental pulmonary aspergillosis in persistently neutropenic rabbits, thus providing a rational basis for further investigations in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0032949096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032949096&partnerID=8YFLogxK

U2 - 10.1093/jac/43.1.95

DO - 10.1093/jac/43.1.95

M3 - Article

C2 - 10381106

AN - SCOPUS:0032949096

VL - 43

SP - 95

EP - 103

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 1

ER -